Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000406326 | SCV000330871 | pathogenic | not provided | 2018-11-23 | criteria provided, single submitter | clinical testing | The c.446-2A>C splice site variant in the MEN1 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. This variant destroys the canonical splice acceptor site in intron 3. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. Based on currently available evidence, we consider c.446-2A>C to be pathogenic and its presence consistent with a diagnosis of multiple endocrine neoplasia type 1 |
Laboratory of Molecular and Cytogenetics, |
RCV003233029 | SCV003930408 | pathogenic | Multiple endocrine neoplasia, type 1 | 2023-04-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003233029 | SCV005845193 | pathogenic | Multiple endocrine neoplasia, type 1 | 2025-01-03 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 2 of the MEN1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with multiple endocrine neoplasia type 1 (MEN1) syndrome (internal data). ClinVar contains an entry for this variant (Variation ID: 280917). Studies have shown that disruption of this splice site results in skipping of exon 3, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic. |